GEP100 regulates epidermal growth factor-induced MDA-MB-231 breast cancer cell invasion through the activation of Arf6/ERK/uPAR signaling pathway  by Hu, Zhenzhen et al.
Available online at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/yexcr
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 1 9 3 2 – 1 9 4 10014-4827 & 2013 E
http://dx.doi.org/10.1
nCorresponing auth
E-mail addressesResearch ArticleGEP100 regulates epidermal growth factor-induced
MDA-MB-231 breast cancer cell invasion through the
activation of Arf6/ERK/uPAR signaling pathwayZhenzhen Hua, Rui Xub, Jiaojing Liuc, Yujie Zhangc, Jun Dua,d, Weixing Lie, Wanqiu Zhange,
Yueying Lif, Yichao Zhua,d,n, Luo Gua,d,n
aState Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029, PR China
bDepartment of Physiology, Nanjing Medical University, Nanjing, Jiangsu 210029, PR China
cDepartment of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu 210029, PR China
dCancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, PR China
eMedicine Technique School, Taizhou Polytechnic College, Taizhou, Jiangsu 225300, PR China
fSchool of Medical Sciences and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, PR Chinaa r t i c l e i n f o r m a t i o n
Article Chronology:
Received 27 November 2012
Received in revised form
10 May 2013
Accepted 29 May 2013









ors at: Cancer Center, Nanji
: zhuyichao@njmu.edu.cn
Open access under Ca b s t r a c t
GEP100, a guanine nucleotide exchanging factor (GEF) for Arf6, plays a pivotal role in promoting
breast cancer cell invasion both in vitro and in vivo. However, the precise mechanism for GEP100-
mediated cell invasion is still poorly understood. In this study, we found that down-regulation of
endogenous GEP100 in MDA-MB-231 cells signiﬁcantly inhibited EGF-induced cell invasion,
which was rescued by over-expression of ectopic GEP100. EGF increased Arf6 activity, ERK
phosphorylation, and uPAR expression in a time dependent manner. Additionally, blocking Arf6
with Arf6 siRNA largely abolished EGF-induced cell invasion. GEP100 siRNA or Arf6 siRNA
suppressed EGF-induced ERK activity and uPAR expression. Furthermore, blocking ERK signaling
with U0126, a speciﬁc inhibitor for MEK, markedly inhibited EGF-induced uPAR expression and
consequently cell invasion. Inhibition of uPAR expression by uPAR siRNA also signiﬁcantly
abolished EGF-induced cell invasion. Taken together, this study illustrates that GEP100 regulates
an Arf6/ERK/uPAR signaling cascade in EGF-induced breast cancer cell invasion. These ﬁndings
could provide a rationale for designing new therapies based on inhibition of breast cancer
metastasis.
& 2013 Elsevier Inc. Open access under CC BY-NC-ND license. Introduction
Epidermal growth factor (EGF) and its receptor (EGFR) are
frequently found to be over-expressed in multiple types of
cancer cells, including breast cancer cells, which correlatesng Medical University, 140
(Y. Zhu), lgu@njmu.edu.cn
C BY-NC-ND license. with tumor development and progression [1]. Constitutive
EGFR activation by EGF contributes to the transition from a
localized primary tumor mass into an invasive phenotype
leading to secondary metastases [2,3]. Although the role of EGF/
EGFR in tumor invasion has been reported, the downstreamHanzhong Road, Nanjing, Jiangsu 210029, China. Fax: +86 25 8686 2016.
(L. Gu).
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characterized.
Accumulating evidence has strongly implicated GEP100 as a key
mediator of tumor invasion, particularly that induced by EGF
[4–8]. In response to EGF stimulation, GEP100 binds directly to
Tyr1068/1086-phosphorylated EGFR via its pleckstrin homology
(PH) domain to induce breast cancer invasion [4]. Other studies
demonstrated that GEP100 also binds directly to Tyr1139/1196-
phosphorylated Her2 via its PH domain to induce lung cancer
invasion [5]. Furthermore, studies by Xie CG et al. [6] have shown
that down-regulation of GEP100 in pancreatic cancer cells sig-
niﬁcantly decreases invasive activity and the expression level of
GEP100 protein is closely related to the invasive ability of human
pancreatic cancer cell lines. While a role for GEP100 in mediating
tumor invasion has been strongly suggested, the precise mechan-
ism by which GEP100 performs this role is not well understood.
The urokinase plasminogen activator receptor (uPAR) is a highly
glycosylated and membrane-bound single-chain protein [9].
Increased levels of uPAR, which have been considered to be
prognostically signiﬁcant, have been clearly demonstrated to be
essential for the maintenance of the invasive and metastatic
phenotypes of cancer cells [10–12]. A growing body of evidence
indicates that synthesis of uPAR is increased by a diverse number
of growth factors such as EGF [13,14]. The activation of extra-
cellular signal-regulated kinase (ERK) has been identiﬁed as aFig. 1 – GEP100 is required for EGF-induced cell invasion. (A) Protei
uPAR and GEP100 expression in MDA-MB-231 cells were determine
negative control. (B) The effect of siRNA on the intracellular levels
transfected with GEP100-siRNA or scrambled siRNA (irr siRNA) wer
loading control. (C) Effect of the GEP100-siRNA on EGF-stimulated c
or rescued with GEP100-WT as indicated were subjected to a trans
n: Po0.05, referring to the difference between cells treated with a
between the cells transfected with GEP100 siRNA and the cells trapotent modulator of uPAR expression in many types of cancer
cells [15–17]. In addition, a recent study has shown that the
activation of ERK and the expression of uPAR are regulated by
Arf6 during tubular development, which can be speciﬁcally
activated by GEP100 [18]. Furthermore, our previous study has
indicated that GEP100 regulates ERK activation during EGF-
induced hepatoma cell migration [19]. Here, we investigated
whether ERK and uPAR might be involved in EGF-induced breast
cancer cell invasion. The results indicate that EGF stimulates
breast cancer cell invasion through GEP100-dependent activation
of the Arf6/ERK/uPAR signaling pathway.Results
GEP100 mediates EGF-induced cell invasion via activating
Arf6
To evaluate whether GEP100 mediates EGF-induced breast cancer
cell invasion, we chose the highly invasive MDA-MB-231 cells,
which expressed higher levels of GEP100 than MCF-7, a much less
aggressive breast cancer cell line (Fig. 1A). Down-regulation of
GEP100 protein synthesis after transfecting MDA-MB-231 cells
with GEP100 siRNA was conﬁrmed by Western blotting (Fig. 1B).
Matrigel invasion assay showed that the number of cellsn levels of GEP100 and uPAR in MDA-MB-231 cells. The levels of
d as described in ‘Materials and methods’. MCF-7 cells used as
of GEP100. Total protein extracts from MDA-MB-231 cells
e analyzed by western blotting for GEP100. GAPDH was used a
ell invasion. MDA-MB-231 cells transfected with GEP100-siRNA
well invasion assay in the presence of 10 ng/mL EGF for 24 h.
nd without EGF. #: Po0.05 (t-test), referring to the difference
nsfected with scrambled siRNA (irr siRNA) plus EGF.
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EGF treatment (Fig. 1C). GEP100 knockdown cells exhibited
signiﬁcantly diminished capacity to invade, which was rescued
by re-expressing GEP100 (Fig. 1C).
It has been reported that GEP100 is speciﬁcally responsible for
Arf6 activation [20]. To determine whether Arf6 is the down-
stream target of GEP100 during EGF-induced MDA-MB-231 cell
invasion, we examined Arf6 activation after EGF treatment by
pulldown assays. The results revealed a time-dependent increase
in Arf6 activity following EGF treatment as evidenced by GTP-
bound Arf6. Arf6 activation was signiﬁcantly induced 5 minutes
after EGF stimulation, peaked at 15 min, and then gradually
returned to basal levels (Fig. 2A). GEP100 siRNA signiﬁcantly
abolished Arf6 activation (Fig. 2B). To investigate whether Arf6
activation is required for EGF-stimulated MDA-MB-231 cell inva-
sion, we blocked Arf6 activation by transfecting cells with Arf6Fig. 2 – Activation of Arf6 mediated by GEP100 is required for EGF-i
starved cell monolayers were treated with 10 ng/mL EGF for the in
pulldown assays as described in ‘Materials and methods’. (B) GEP1
with GEP100-siRNA were stimulated with EGF for 15 min, and Arf6
intracellular levels of Arf6. Total protein extracts from MDA-MB-23
(irr siRNA) were analyzed by western blotting for Arf6. GAPDH was
EGF-stimulated cell invasion. MDA-MB-231 cells transfected with A
to a transwell invasion assay in the presence of 10 ng/mL EGF for 2
with and without EGF. #: Po0.05 (t-test), referring to the differen
transfected with scrambled siRNA (irr siRNA) plus EGF.siRNA (Fig. 2C). The results showed that invasion was signiﬁcantly
suppressed in cells transfected with Arf6 siRNA (Fig. 2D) prior to
EGF treatment, indicating that GEP100 mediates EGF-induced
breast cancer cell invasion by activating Arf6.
GEP100 regulates ERK activation through Arf6 signaling
during EGF-induced cell invasion
Since the activation of ERK participates in both Arf6-mediated
cancer cell invasion [21,22] and the regulation of EGF/GEP100-
stimulated hepatoma cell migration [19], we wondered whether
GEP100 could also regulate EGF-induced MDA-MB-231 breast
cancer cell invasion via ERK activation. We hence ﬁrst investigated
the effect of GEP100/Arf6 on ERK activation using Western
blotting assays. We found that the levels of phospho-ERK were
signiﬁcantly increased 15 min after EGF stimulation, whereas thenduced cell invasion. (A) EGF induces activation of Arf6. Serum-
dicated times. Cellular lysates were assayed for active Arf6 by
00-siRNA transfection inhibits Arf6 activation. Cells transfected
-GTP levels were examined. (C) The effect of siRNA on the
1 cells transfected with Arf6-siRNA (siArf6) or scrambled siRNA
used a loading control. (D) Effect of the Arf6-siRNA (siArf6) on
rf6-siRNA or rescued with Arf6-WT as indicated were subjected
4 h. *: Po0.05, referring to the difference between cells treated
ce between the cells transfected with Arf6 siRNA and the cells
Fig. 3 – ERK is a downstream target of GEP100/Arf6 pathway and its activation is required for EGF-induced cell invasion. (A) Effect
of EGF on the activation of ERK. MDA-MB-231 cells were starved overnight, followed by treatment with 10 ng/mL EGF for the
indicated times. Phosphorylation of ERK at Thr202/Tyr204 was determined as described in ‘Materials and methods’. (B) GEP100-
siRNA transfection inhibits ERK activation. Cells transfected with GEP100-siRNA were stimulated with EGF for 15 min, and the
activation of ERK was examined. (C) EGF-activated ERK depends on Arf6. Cells transfected with Arf6-siRNA were stimulated with
EGF for 15 min, and the activation of ERK was examined. (D) Effect of ERK inhibitor on EGF-stimulated cell invasion. After
pretreatment with 10 μM U0126 for 60 min, MDA-MB-231 cells were incubated with 10 ng/mL EGF for 24 h and the cell invasion
rate was determined by Transwell invasion assay. n: Po0.05, referring to the difference between cells treated with and those
without EGF. #: Po0.05 (t-test), referring to the difference between the cells transfected with Arf6-siRNA or GEP100 siRNA plus EGF
and the cells transfected with scrambled siRNA (irr siRNA) plus EGF.
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 1 9 3 2 – 1 9 4 1 1935total levels of ERK remained unchanged (Fig. 3A). Down-
regulation of GEP100 (Fig. 3B) or Arf6 (Fig. 3C) by speciﬁc siRNAs
largely inhibited EGF-induced ERK activity. These results suggest
that GEP100/Arf6 act as upstream effectors of ERK activation.
Next, we sought to determine whether ERK activation is
required for EGF-induced breast cancer cell invasion. Pre-
treatment of the cells with 10 μM U0126 resulted in inhibition
of EGF-induced cell invasion (Fig. 3D). These results suggest that
ERK acts as a downstream target of GEP100 and Arf6 in mediating
EGF-stimulated breast cancer cell invasion.
GEP100 regulates uPAR expression through Arf6 signaling
during EGF-induced cell invasion
uPAR expression has been shown to be promoted by EGF in
various types of cancer cells [23–26]. We here examined whether
the expression of uPAR was also up-regulated in MDA-MB-231cells after EGF stimulation. As shown in Fig. 4A, uPAR expression
was up-regulated in MDA-MB-231 cells, and the maximum level
of expression was observed 12 h after EGF treatment. RT-PCR
assays demonstrated that uPAR mRNA was also signiﬁcantly
augmented by EGF in these cells, reaching peak level at 4 h
(Fig. 4B). We next examined whether uPAR was the downstream
target of GEP100/Arf6 in MDA-MB-231 cells. The siRNAs against
GEP100 and Arf6 noticeably attenuated EGF-induced increases in
levels of uPAR mRNA and protein (Fig. 4C–F). These data suggest
that uPAR is a downstream target of GEP100/Arf6 during EGF
stimulation in MDA-MB-231 cells.
High level of uPAR was detected in MDA-MB-231 cells (Fig. 1A).
To determine whether EGF-induced cell invasion is uPAR-depen-
dent, we blocked endogenous uPAR expression using siRNA
speciﬁc for uPAR. The siRNA against human uPAR reduced the
protein level of uPAR as assessed by Western blotting (Fig. 4G)
and signiﬁcantly reduced EGF-induced invasion of MDA-MB-231
Fig. 4 – uPAR is required for EGF-induced cell invasion. (A&B) EGF induces uPAR expression in MDA-MB-231 cells. Conﬂuent, serum-
starved cells were incubated under EGF treatment for the indicated periods. Total cellular proteins or RNAs were extracted and analyzed
for uPAR expression in MDA-MB-231 cells by western blotting and RT-PCR assays. (C&D) GEP100-siRNA transfection inhibit uPAR
expression. Cells transfected with GEP100-siRNA were stimulated with EGF for 12 h, and the expression of uPAR was analyzed by western
blotting (C) and RT-PCR (D). (E&F) EGF-induced uPAR expression depends on Arf6. Cells transfected with Arf6-siRNAwere stimulated with
EGF for 12 h, and the expression of uPAR was analyzed by western blotting (E) and RT-PCR (F). (G) The effect of siRNA on the intracellular
levels of uPAR. Total protein extracts from MDA-MB-231 cells transfected with siRNA-uPAR (siuPAR) or scrambled siRNA (irr siRNA) were
analyzed by western blotting for uPAR. GAPDH was used a loading control. (H) Effect of the siRNA-uPAR on EGF-stimulated cell invasion.
MDA-MB-231 cells transfected with siRNA-uPAR (siuPAR) as indicated were subjected to a transwell invasion assay in the presence of
10 ng/mL EGF for 24 h. n: Po0.05, referring to the difference between cells treated with and those without EGF. #: Po0.05 (t-test), referring
to the difference between the cells transfected with Arf6–siRNA or GEP100 siRNA plus EGF and the cells transfected with scrambled siRNA
(irr siRNA) plus EGF.
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that uPAR is a downstream target of GEP100/Arf6 whose expres-
sion is required for EGF-induced MDA-MB-231 cell invasion.GEP100/Arf6-dependent uPAR expression requires ERK
activity
Previous reports have shown that growth factor-induced uPAR
expression is ERK activation-dependent [16,18,27]. We examined
whether EGF-induced uPAR expression is also ERK-dependent in
our system. We blocked ERK activity by treating MDA-MB-231
cells with U0126, a speciﬁc inhibitor for MEK, and examined uPAR
expression after EGF stimulation. The results showed that 10 μM
U0126 largely inhibited EGF-induced uPAR expression compared
with that of the control untreated cells (Fig. 5A, B). To determine
whether uPAR regulates ERK activation in these cancer cells, we
transfected cells with uPAR siRNA followed by treatment
with EGF. We found that inhibition of uPAR expression did not
alter EGF-induced phosphorylation of ERK (Fig. 5C). These
results suggest that ERK acts as an upstream molecule of uPAR
signaling.Fig. 5 – GEP100-dependent uPAR expression requires ERK activity. (A
231 cells were treated with 10 μM U0126 for 60 min prior to EGF t
expression analysis. (C) EGF-mediated ERK activation is uPAR inde
stimulated with EGF for 15 min, and then subjected to ERK activati
treated with and those without EGF. #: Po0.05 (t-test), referring t
relative to cells treated with EGF alone.Discussion
GEP100 has been proven to be involved in the metastasis of
various types of cancer [4–8]. In the present study, EGF-induced
invasive activity of MDA-MB-231 breast cancer cells was signiﬁ-
cantly decreased when the expression of GEP100 was inhibited.
Therefore, GEP100 plays a signiﬁcant role in EGF-induced breast
cancer cell invasion in vitro.
A primary observation in the present study is that EGF induced
Arf6 activation in a time-dependent manner in breast cancer cells.
Arf6 is a known downstream target of GEP100 and can be
activated by various growth factors, including vascular growth
factor [28], colony-stimulating factor [29] and G protein coupled
receptor agonists [30]. Arf6 activation promotes invasion and
metastasis of various types of cancer cells [4,21,22,31,32]. Tague
et al. have shown that activation of Arf6 mediates hepatocyte
growth factor (HGF)-stimulated melanoma cell invasion and is
correlated with the progression of melanoma cancer [21]. Simi-
larly, our results indicate that EGF-stimulated cell invasion was
dramatically diminished when Arf6 activation was blocked. More-
over, EGF-induced Arf6 activation was suppressed by ectopic
expression of GEP100 siRNA. Therefore, our results suggest&B) EGF-mediated expression of uPAR requires ERK. MDA-MB-
reatment (10 ng/mL) for 12 h, and then subjected to uPAR
pendent. Cells transfected with uPAR siRNA (siuPAR) were
on analysis. n: Po0.05, referring to the difference between cells
o the difference between cells treated with EGF plus U0126
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activation.
We next examined the potential downstream effector of
GEP100/Arf6 in our system. ERK is the major signaling molecule
regulating in vitro and in vivo tumor cell invasion [33–35]. A
recent study has demonstrated that Arf6 is required for HGF-
induced melanoma cell invasion via activation of ERK signaling
[21]. Tushir et al. [18] also reported that ERK is implicated in Arf6-
mediated epithelial tubule development in response to HGF. In
agreement with these ﬁndings, our results showed that EGF
induced a time-dependent increase in ERK activity. Inhibition of
ERK activity by U0126 treatment signiﬁcantly prevented EGF-
induced cell invasion, suggesting that EGF-induced ERK activation
is responsible for the invasion of these cells. Furthermore,
inhibition GEP100 or Arf6 activity by siRNA blocked EGF-
induced ERK activation. Therefore, it is reasonable to speculate
that EGF-induced ERK activation is indispensible for GEP100/Arf6
mediated breast cancer cell invasion.
Signals mediated by uPAR have been shown to play critical roles
in the regulation of tumor invasion [36–38]. A recent study has
found that uPAR is required for EGF-induced gastric cancer cell
invasion [16]. uPAR has also been implicated in Arf6-mediated
epithelial tubule development in response to HGF [18]. Consistent
with these reports, our results revealed that EGF-induced cell
invasion was associated with an increase in uPAR expression.
Down-regulation of uPAR expression by siRNA signiﬁcantly sup-
pressed EGF-induced cell invasion. Moreover, our results showed
that GEP100 siRNA or Arf6 siRNA could also inhibit EGF-induced
uPAR expression. Consequently, we conclude that uPAR is a
downstream component of GEP100/Arf6 signaling pathway in
EGF-stimulated breast cancer cell invasion. Previous study has
reported that EGFR-GEP100-Arf6-AMAP1 signaling pathway is
speciﬁc to breast cancer invasion and metastasis [8]. Meanwhile,
our data support the concept that EGF is capable of inducing uPAR
expression through the Arf6 signaling, which is associated the
presence of GEP100 with breast cancer cell invasion.
In some cell types, ERK is a downstream target of the uPAR
signaling cascade and inhibition of uPAR is sufﬁcient to suppress
ERK activation [39–42]. However, in our study, blocking ERK
activity signiﬁcantly prevented EGF-induced uPAR expression.
Furthermore, siRNA-mediated down-regulation of uPAR in MDA-
MB-231 cells did not alter EGF-induced ERK activation. A similar
observation was made by Beak MK et al. in which ERK promoted
lithocholic acid (LCA)-induced colon cancer cell invasion via up-
regulation of uPAR [17]. Therefore, it is possible that EGF induces
uPAR expression via ERK pathway and, in turn, stimulates the
invasiveness of breast cancer cells. These different results
obtained by different groups reﬂect the complicated signaling
circuits in different cellular settings.
It is well known that signaling pathways may regulate uPAR
expression in cancer cells by promoting the binding of speciﬁc
transcription factors on the uPAR promoter [15,43]. The transcrip-
tion of uPAR is controlled by a host of transcription factors such as
AP-1 and NF-κB. However, it remains unclear whether GEP100/
Arf6 mediates uPAR expression through regulation of these
transcription factors in our system. A recent study showed that
activation of transcription factors AP-1 and NK-ĸB is responsible
for uPAR expression induced by EGF in human gastric carcinoma
cells [18]. In addition, AP-1 signaling is found to function in LCA-
induced uPAR expression in colon cancer cells [17], suggestingthat the relative contributions of these transcription factors vary
depending on the cell line and the stimulus used. The role that
transcription factors play downstream of ERK in controlling uPAR
expression and cell invasion remains to be determined. On the
other hand, recent studies indicate that co-expression of GEP100
and EGFR is indicative of the malignant phenotype of primary
breast cancer [4]. In addition, co-expression of EGFR and uPAR has
been observed in some human cancers [44]. Moreover, in our
study, we found that MDA-MB-231 cells expressed high levels of
GEP100 and uPAR, and importantly, EGF induced the invasion of
these cells through GEP100 and uPAR. Therefore, it is possible that
co-expression of these two proteins is associated with the
malignant phenotype of human breast cancer. Further studies
are needed to decipher whether co-expression of GEP100 and
uPAR is indicative of the malignant phenotype of human breast
cancer.
In summary, we have identiﬁed a signaling pathway that is
implicated in EGF-induced breast cancer cell invasion. EGF treat-
ment can lead to the activation of the GEP100/Arf6/ERK/uPAR
cascade in breast cancer cells and contribute to breast cancer cell
invasion. These ﬁndings elucidate a molecular pathway linking
GEP100/Arf6 signaling with uPAR activation in governing cell
invasion, which provides a rational for designing new molecular
target for manipulating breast cancer.Materials and methods
Cell culture
Human breast cancer cell lines MDA-MB-231 and MCF-7 (ATCC,
Manassas, VA) were maintained in high glucose Dulbecco's
modiﬁed Eagle's medium (DMEM) (Gibco, Grand Island, NY)
supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone,
Logan, UT), 100 units penicillin/mL and 100 mg/mL streptomycin
in a humidiﬁed atmosphere at 37 1C with 5% CO2. Cells were made
quiescent by serum starvation overnight followed by drug
treatment.Plasmids, siRNA and transfection
pEGFP-N1 vector containing wild type GEP100 (GEP100-WT)
insert was kindly provided by Dr. Akimasa Someya (Juntendo
University School of Medicine, Japan). The sequences of small
interfering RNA (siRNA) for GEP100 #1: GAUGCUAGAACGAAA-
GUAUTT, #2: GCGAGAGCUAAAGACCAAUTT, #3: CCGGAGCA-
GAUAUCAAAGUTT, for Arf6 #1: CGUGGAGACGGUGACUUACTT,
#2: GCACCGCAUUAUCAAUGACCGTT, #3: UCCUCAUCUUCGCCAA-
CAATT, for uPAR #1: GGUGAAGAAGGGCGUCCAATT, #2: GAAGA-
GACUUUCCUCAUUGTT, #3: GGUGACGCCUUCAGCAUGATT and for
scrambled siRNA sequence 5'–UUCUCCGAACGUGUCACGUTT–3'
(GenePharma Co., Shanghai, China) were transfected into MDA-
MB-231 cells. Cells were grown until approximately 60% conﬂuent
and then transfected with indicated plasmids or siRNAs using
Lipofectamine 2000 as instructed by the manufacturer (Invitro-
gen, Carlsbad, CA, USA). These cells were allowed to grow for 24–
48 h post transfection before treatment with EGF where
indicated.
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The Matrigel invasion assay was performed using a transwell
coated with 25 μg Matrigel (Sigma, St. Louis, MO, USA). 1105
cells in DMEM with 0.1% bovine serum albumin (BSA) were
seeded into the upper compartment of polycarbonate membrane
transwell inserts. The lower compartment was ﬁlled with DMEM
containing 10 ng/mL EGF as a chemoattractant. After the incuba-
tion for 24 h, cells that had migrated to the lower surface were
ﬁxed in methanol for 20 min and stained with 0.1% crystal violet
for 20 min. The cells on the upper surface of the transwell
membrane were wiped off with a cotton swab and the number
of cells that adhered onto the lower surface was counted in 5
randomly selected ﬁelds.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNAs were isolated with the TRIzol reagent according to the
manufacturer's protocol (Invitrogen, Carlsbad, CA). cDNA was
synthesized using the SuperScript First Strand Synthesis System
(Invitrogen) and ampliﬁed by polymerase chain reaction (PCR)
using the following primers: GAPDH: 5'–TGAACGGGAAGCT-
CACTGG–3' (sense) and 5'–TCCACCACCCTGTTGCTGTA–3' (anti-
sense); uPAR: 5'–ACGACACCTTCCACTTCCTG–3' (sense) 5'–
ACAGTCTGGCAGTCATTAGC–3' (antisense). PCRs for GAPDH and
uPAR were performed for 26 cycles and 28 cycles, respectively,
with each cycle for 30 s at 95 1C, 30 s at 55 1C and 30 s at 72 1C.
The PCR products were resolved by electrophoresis on 1% agarose.
Western blotting
Cellular lysates and western blotting assays were performed as
previously depicted [45,46]. The following antibodies were used:
rabbit anti-GEP100 (Sigma, St. Louis, MO, USA), mouse anti-Arf6
and goat anti-uPAR (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), rabbit anti-ERK1/2 and anti-phospho-ERK1/2 (Thr202/
Tyr204) (Cell Signaling Technology, Boston, MA, USA), and mouse
anti-GAPDH antibody (Chemicon, Temecula, CA, USA).
Pulldown assays
Arf6 activity was measured as previously depicted [19]. In brief,
equal volumes of total cellular protein were incubated with GST-
GGA3 for detection of active Arf6 (gifts from James E Casanova,
University of Virginia, VA) beads captured on MagneGST Glu-
tathione Particles (Promega, Madison, WI) for 1 h at 4 1C. The
particles were then washed three times with washing buffer
containing 4.2 mM Na2HPO4, 2 mM KH2PO4, 280 mM NaCl, and
10 mM KCl (pH7.2), resuspended in 2 SDS sample buffer and
subjected to immunoblotting analysis by using a mouse anti-Arf6
antibody (Santa Cruz Biotechnology).
Statistical analysis
Statistical analysis was carried out using the SPSS statistical
software package version 17 (SPSS Inc., Chicago, IL). Student's t
test was used to analyze the differences between two groups.
When comparisons between multiple groups were carried out,
one-way ANOVA followed by SNK tests were employed. Statistical
signiﬁcance was considered at Po0.05.Conﬂict of interest
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